Tags » Antiplatelet Therapy

AstraZeneca Drug 'Approaching The Point Of Diminishing Returns'

After a heart attack (myocardial infarction or MI) patients remain at high risk for recurrent events. The precise role of blood thinning with dual antiplatelet therapy to lower this risk has been the subject of considerable disagreement.   43 more words

Interventional Cardiology & Surgery

“Very” Very Late Stent Thrombosis

The field of interventional cardiology was born on the shoulders of Andreas Gruentzig, MD, who performed the first balloon angioplasty in 1977.  Despite the initial skepticism toward the procedure, balloon angioplasty became a commonplace treatment of coronary artery disease.  516 more words

A splitting headache

A 37 year old woman presented to our hospital with a 9 day history of persistent headaches. Her past medical history was significant for infrequent ‘migraine’ headaches which had previously been associated with visual disturbance. 730 more words

Royal Adelaide Hospital

FDA Reviewers Deliver Split Opinion On The Medicines Company's Cangrelor

FDA reviewers presented two dramatically different views of The Medicines Company’s investigational new drug cangrelor. One reviewer says the drug should not be approved without a new trial and even states that the CHAMPION trials “were conducted unethically” and should not be approved “on that fact alone.”  But two other reviewers recommend approval. 10 more words

Policy & Ethics

Current Diagnosis and Treatment Cardiology

Current Diagnosis and Treatment Cardiology

Author: Michael Crawford
ISBN: 9780071801270
©2014 | 4th Edition | 608 pages | Paperback
Pub Date: OCT-13
Price: US$ 80.00… 168 more words

General Medicine

Secondary prevention for patients after a myocardial infarction: summary of updated NICE guidance

Source: BMJ, 13th November 2013

Follow this link for the fulltext http://www.bmj.com/content/347/bmj.f6544

Date of publication: November 2013

Publication type: Practice guidelines

In a nutshell: 49 more words

Secondary Prevention